Adjuvant immunotherapy for non-small cell lung cancer

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 650-661

  Tucker, Zachary C G ^a   Laguna, Benjamin A ^a   Moon, Edmund ^b   Singhal, Sunil ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adjuvant immunotherapy; Immunotherapy; Non small cell lung cancer; Surgery

Indexed keywords

CANCER VACCINE; IMMUNOMODULATING AGENT; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNITED STATES;

CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; NEOPLASM STAGING;

EID: 84861713665     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.11.008     Document Type: Review

References (100)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Sugimura H, Nichols FC, Yang P, et al. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg. 2007;83:409-417; discussioin 17-18.
3. Aliperti L.A., Predina J.D., Vachani A., Singhal S. Local and systemic recurrence is the Achilles heel of cancer surgery. Ann Surg Oncol 2011, 18:603-607.
4. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 1997, 111:1710-1717.
5. Pisters K.M., Le Chevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. J Clin Oncol 2005, 23:3270-3278.
6. Shakhar G., Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients?. Ann Surg Oncol 2003, 10:972-992.
7. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. The Lung Cancer Study Group. N Engl J Med. 1986;315:1377-1381.
8. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet. 1998;352:257-263.
9. Machtay M., Lee J.H., Shrager J.B., Kaiser L.R., Glatstein E. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol 2001, 19:3912-3917.
10. Okawara G., Ung Y.C., Markman B.R., Mackay J.A., Evans W.K. Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 2004, 44:1-11.
11. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899-909.
12. Mineo T.C., Ambrogi V., Corsaro V., Roselli M. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer. Eur J Cardiothorac Surg 2001, 20:378-384.
13. Strauss GM HJ, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol. 2004;22:621s (suppl; abstr 7019).
14. Winton TL LR, Johnson D, et al. A prospective randomised trial of adjuvant vinorelbine and cisplatin in completely resected stage IB and II non-small cell lung cancer. Intergroup JBR.10. J Clin Oncol. 2004;22:621s (suppl; abstr 7018).
15. Arriagada R., Bergman B., Dunant A., et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360.
16. Scagliotti G.V., Fossati R., Torri V., et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003, 95:1453-1461.
17. Tada H., Tsuchiya R., Ichinose Y., et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 2004, 43:167-173.
18. Ichinose Y., Hara N., Ohta M., et al. Postoperative adjuvant chemotherapy in non-small cell lung cancer: prognostic value of DNA ploidy and post-recurrent survival. J Surg Oncol 1991, 46:15-20.
19. Ichinose Y., Yano T., Yokoyama H., et al. Postrecurrent survival of patients with non-small-cell lung cancer undergoing a complete resection. J Thorac Cardiovasc Surg 1994, 108:158-161.
20. Yoshino I., Yohena T., Kitajima M., et al. Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs. Ann Thorac Cardiovasc Surg 2001, 7:204-209.
21. Swann J.B., Smyth M.J. Immune surveillance of tumors. J Clin Invest 2007, 117:1137-1146.
22. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011, 71:3-10.
23. Hirschowitz E.A., Yannelli J.R. Immunotherapy for lung cancer. Proc Am Thorac Soc 2009, 6:224-232.
24. Mocellin S., Rossi C.R., Lise M., Marincola F.M. Adjuvant immunotherapy for solid tumors: from promise to clinical application. Cancer Immunol Immunother 2002, 51:583-595.
25. Burnet F.M. Immunological recognition of self. Science 1961, 133:307-311.
26. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
27. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360.
28. Buell J.F., Gross T.G., Woodle E.S. Malignancy after transplantation. Transplantation 2005, 80:S254-S264.
29. Clark W.H., Elder D.E., Guerry Dt., et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989, 81:1893-1904.
30. Clemente C.G., Mihm M.C., Bufalino R., et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77:1303-1310.
31. Scanlan M.J., Simpson A.J., Old L.J. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004, 4:1.
32. Ferradini L., Mackensen A., Genevee C., et al. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest 1993, 91:1183-1190.
33. Zorn E., Hercend T. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol 1999, 29:592-601.
34. Zorn E., Hercend T. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur J Immunol 1999, 29:602-607.
35. Kerr K.M., Johnson S.K., King G., et al. Partial regression in primary carcinoma of the lung: does it occur?. Histopathology 1998, 33:55-63.
36. Mami-Chouaib F., Echchakir H., Dorothee G., Vergnon I., Chouaib S. Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen. Immunol Rev 2002, 188:114-121.
37. Echchakir H., Vergnon I., Dorothee G., et al. Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung. Int Immunol 2000, 12:537-546.
38. Ruffini E, Asioli S, Filosso PL, et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg. 2009;87:365-371; discussion 71-72.
39. Sarraf K.M., Belcher E., Raevsky E., et al. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009, 137:425-428.
40. Bradbury P.A., Shepherd F.A. Immunotherapy for lung cancer. J Thorac Oncol 2008, 3:S164-S170.
41. Sorrentino R., Morello S., Forte G., et al. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am J Respir Crit Care Med 2011, 183:1369-1379.
42. Nemunaitis J.J. Gene immunotherapy for non-small cell lung cancer. Methods Mol Biol 2009, 542:499-514.
43. Lee G., Walser T.C., Dubinett S.M. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr Opin Pulm Med 2009, 15:303-307.
44. Takenoyama M., Yoshino I., Fujie H., et al. Autologous tumor-specific cytotoxic T lymphocytes in a patient with lung adenocarcinoma: implications of the shared antigens expressed in HLA-A24 lung cancer cells. Jpn J Cancer Res 1998, 89:60-66.
45. Hanagiri T., Yoshino I., Takenoyama M., et al. Effects of interleukin-12 on the induction of cytotoxic T lymphocytes from the regional lymph node lymphocytes of patients with lung adenocarcinoma. Jpn J Cancer Res 1998, 89:192-198.
46. So T., Takenoyama M., Sugaya M., et al. Generation of autologous tumor-specific T cell clones from a patient with adenosquamous carcinoma of the lung. Jpn J Clin Oncol 2001, 31:311-317.
47. Coulie P.G., Hanagiri T., Takenoyama M. From tumor antigens to immunotherapy. Int J Clin Oncol 2001, 6:163-170.
48. Yasumoto K., Hanagiri T., Takenoyama M. Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer. Gen Thorac Cardiovasc Surg 2009, 57:449-457.
49. Hogan K.T., Eisinger D.P., Cupp S.B., et al. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res 1998, 58:5144-5150.
50. Echchakir H., Mami-Chouaib F., Vergnon I., et al. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001, 61:4078-4083.
51. Karanikas V., Colau D., Baurain J.F., et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001, 61:3718-3724.
52. Takenoyama M., Baurain J.F., Yasuda M., et al. A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer 2006, 118:1992-1997.
53. Ichiki Y., Takenoyama M., Mizukami M., et al. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J Immunol 2004, 172:4844-4850.
54. Gjertsen M.K., Bjorheim J., Saeterdal I., Myklebust J., Gaudernack G. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 1997, 72:784-790.
55. Mandruzzato S., Brasseur F., Andry G., Boon T., van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997, 186:785-793.
56. Makita M., Hiraki A., Azuma T., et al. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 2002, 8:2626-2631.
57. Vlad A.M., Kettel J.C., Alajez N.M., Carlos C.A., Finn O.J. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004, 82:249-293.
58. Szelachowska J., Jelen M., Kornafel J. Prognostic significance of intracellular laminin and Her2/neu overexpression in non-small cell lung cancer. Anticancer Res 2006, 26:3871-3876.
59. Bria E., Visca P., Novelli F., et al. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer. Eur J Surg Oncol 2008, 34:593-598.
60. Karanikas V., Tsochas S., Boukas K., et al. Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: implications for immunotherapy. Cancer Biol Ther 2008, 7:345-352.
61. Tajima K., Ito Y., Demachi A., et al. Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes. Int J Cancer 2004, 110:403-412.
62. Nagata Y., Hanagiri T., Takenoyama M., et al. Identification of the HLA-Cw*0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient. Clin Cancer Res 2005, 11:5265-5272.
63. Sugaya M., Takenoyama M., Shigematsu Y., et al. Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung. Int J Cancer 2007, 120:1055-1062.
64. Kim S.K., Wu X., Ragupathi G., et al. Impact of minimal tumor burden on antibody response to vaccination. Cancer Immunol Immunother 2011, 60:621-627.
65. Ochsenbein A.F., Klenerman P., Karrer U., et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 1999, 96:2233-2238.
66. Roscoe P., Ludgate S., et al. A controlled trial of BCG immunotherapy in bronchogenic carcinoma treated by surgical resection. Cancer Immunol Immunother 1977, 3:115-118.
67. Hollinshead A.C., Stewart T.H., Herberman R.B. Delayed-hypersensitivity reactions to soluble membrane antigens of human malignant lung cells. J Natl Cancer Inst 1974, 52:327-338.
68. Hollinshead A.C., Stewart T.H. Specific and nonspecific immunotherapy as an adjunct to curative surgery for cancer of the lung. Yale J Biol Med 1981, 54:367-379.
69. Takita H., Hollinshead A.C., Adler R.H., et al. Adjuvant, specific, active immunotherapy for resectable squamous cell lung carcinoma: a 5-year survival analysis. J Surg Oncol 1991, 46:9-14.
70. Yoshimatsu T., Yoshino I., Ohgami A., et al. Expression of the melanoma antigen-encoding gene in human lung cancer. J Surg Oncol 1998, 67:126-129.
71. Atanackovic D., Altorki N.K., Stockert E., et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004, 172:3289-3296.
72. Atanackovic D., Altorki N.K., Cao Y., et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 2008, 105:1650-1655.
73. Vansteenkiste J ZM, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. 2007;25, No. 18S (June 20 Supplement), 2007: 7554.
74. Vansteenkiste J ZM, Dahabreh A, et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol, 2008 ASCO Annual Meeting. 2008;26: 2008 (May 20 suppl; abstr 7501).
75. Tyagi P., Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009, 10:371-374.
76. Nemunaitis J., Sterman D., Jablons D., et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004, 96:326-331.
77. Nemunaitis J., Jahan T., Ross H., et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 2006, 13:555-562.
78. Hirschowitz E.A., Foody T., Kryscio R., et al. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 2004, 22:2808-2815.
79. Hirschowitz E.A., Foody T., Hidalgo G.E., Yannelli J.R. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 2007, 57:365-372.
80. Kimura H., Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 1997, 80:42-49.
81. Santin A.D. Lymph node metastases: the importance of the microenvironment. Cancer 2000, 88:175-179.
82. Kimura H., Iizasa T., Ishikawa A., et al. Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients. Anticancer Res 2008, 28:1229-1238.
83. Penland S.K., Socinski M.A. Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation. Semin Radiat Oncol 2004, 14:326-334.
84. Li H., Wang C., Yu J., et al. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 2009, 11:1076-1083.
85. Katzel J.A., Fanucchi M.P., Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol 2009, 2:2.
86. Keilholz U., Weber J., Finke J.H., et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002, 25:97-138.
87. Aptsiauri N., Cabrera T., Mendez R., et al. Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 2007, 601:123-131.
88. So T., Takenoyama M., Mizukami M., et al. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res 2005, 65:5945-5952.
89. Baba T., Hanagiri T., Ichiki Y., et al. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B. Cancer Sci 2007, 98:1795-1802.
90. GlobeImmune. A Pilot Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation ClinicalTrialsgov (NCT00655161).
91. Fukuyama T., Ichiki Y., Yamada S., et al. Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro. Cancer Sci 2007, 98:1048-1054.
92. Karanikas V., Zamanakou M., Kerenidi T., et al. Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther 2007, 6:1258-1262.
93. Meloni F., Morosini M., Solari N., et al. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 2006, 67:1-12.
94. Petersen R.P., Campa M.J., Sperlazza J., et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006, 107:2866-2872.
95. Emens L.A., Jaffee E.M. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005, 65:8059-8064.
96. Nowak A.K., Lake R.A., Robinson B.W. Combined chemoimmunotherapy of solid tumours: improving vaccines?. Adv Drug Deliv Rev 2006, 58:975-990.
97. Sinkovics J.G., Horvath J.C. Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts. Int J Oncol 2006, 29:765-777.
98. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008, 8:59-73.
99. GlaxoSmithKline. Cancer Immunotherapeutic GSK1572932A as Adjuvant Therapy for Patients With MAGE-A3-positive Non-Small Cell Lung Cancer. ClinicalTrialsgov (NCT00455572).
100. NCI. Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib as Adjuvant Therapy for Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas. ClinicalTrialsgov (NCT01143545).